½ÃÀ庸°í¼­
»óǰÄÚµå
1762458

¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå, ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ç÷§Æû À¯Çüº°, ¿ëµµº°, Àü´Þ ¸ðµåº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)

Gene Therapy Platform Market Size, Share, & Trends Analysis Report: By Platform Type, By Application, By Delivery Mode (In Vivo, Ex Vivo, and Other), By End Use, and By Region - Market Forecast, 2025-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 129 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 110¾ï 3,541¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

À¯ÀüÀÚ Ä¡·á Ç÷§ÆûÀº Áúº´ÀÇ Ä¡·á³ª ¿¹¹æÀ» À§ÇØ °áÇÔ À¯ÀüÀÚ¸¦ ±³Á¤Çϰųª ´ëüÇÏ´Â À¯ÀüÀÚ ±â¹Ý Ä¡·á¹ýÀ» °³¹ß, Á¦°ø, Á¦Á¶ÇÏ´Â µ¥ »ç¿ëµÇ´Â Á¾ÇÕÀûÀÎ ½Ã½ºÅÛ ¹× ±â¼úÀÔ´Ï´Ù. À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ°¡ ±ÞÁõÇϰí ÀÖÀ¸¸ç, Á¤ºÎ, º¥Ã³ ijÇÇÅ», Á¦¾àȸ»ç¿¡¼­ ¼ö¹é¸¸ ´Þ·¯°¡ ¿¬±¸°³¹ß¿¡ ÅõÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀçÁ¤Àû Áö¿øÀ» ÅëÇØ ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷°ú ¿¬±¸±â°üÀº º¸´Ù ½Å¼ÓÇÏ°Ô ±â¼ú Çõ½ÅÀ» ¼öÇàÇϰí, ÀÓ»ó½ÃÇèÀ» ¼öÇàÇϸç, »õ·Î¿î Ä¡·á¹ýÀ» ½ÃÀå¿¡ Ãâ½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. Èñ±ÍÁúȯ°ú ÁßÁõÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â À¯ÀüÀÚ Ä¡·áÀÇ ³ôÀº ÀáÀç·ÂÀº ÅõÀÚÀڵ鿡°Ô ¸Å·ÂÀûÀÎ ºÐ¾ß°¡ µÇ°í ÀÖ½À´Ï´Ù. ±â¾÷ °£ ÀμöÇÕº´°ú °øµ¿¿¬±¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â º¸´Ù °­·ÂÇÑ Ç÷§Æû°ú ÆÄÀÌÇÁ¶óÀÎÀ» ±¸ÃàÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á ±â¼úÀ» ¹ßÀü½ÃŰ°í ´õ ¸¹Àº ȯÀڵ鿡°Ô Àü ¼¼°èÀûÀ¸·Î Àû¿ë ¹üÀ§¸¦ È®´ëÇϱâ À§Çؼ­´Â ÀÌ·¯ÇÑ °­·ÂÇÑ ÀçÁ¤Àû µÞ¹ÞħÀÌ ÇʼöÀûÀÔ´Ï´Ù.

À¯ÀüÀÚ Ä¡·á Á¦Ç°ÀÇ ÀÓ»ó½ÃÇè ¼º°ø »ç·Ê¿Í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ °Ç¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ Ä¡·á¹ý¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ô¼ö¼º ±ÙÀ§ÃàÁõ¿¡ ´ëÇÑ Á¹°Õ½º¸¶³ª À¯Àü¼º ½Ã·ÂÀúÇÏÁõ¿¡ ´ëÇÑ ·è½ºÅõ¸£³ª¿Í °°Àº Ä¡·á¹ýÀº À¯¸ÁÇϰí Á¾Á¾ »îÀ» º¯È­½ÃŰ´Â °á°ú¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ±àÁ¤ÀûÀÎ ½ÃÇè °á°ú´Â ½ÇÁ¦ ¼¼°è¿¡¼­ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÀÔÁõÇÏ°í ¿¬±¸¿Í ÅõÀÚ¸¦ ÃËÁøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´õ ¸¹Àº Ä¡·á¹ýÀÌ ½ÂÀεǸé À¯ÀüÀÚ Ä¡·áÀÇ ÀáÀç·ÂÀÌ ÀÔÁõµÇ°í ÀÇ»ç, ȯÀÚ, ÁöºÒÀÚ¿¡°Ô ³Î¸® ¹Þ¾Æµé¿©Áú °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼º°øÀº Â÷¼¼´ë Ä¡·áÀÇ ±æÀ» ¿­°í, À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå¿¡ Ȱ·ÂÀ» ºÒ¾î³Ö°í, ±× ¿µ¿ªÀ» ³ÐÇô°¡°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

2024³â ¹ÙÀÌ·¯½º º¤ÅÍ Ç÷§Æû ºÎ¹®Àº ¼¼Æ÷ ³» À¯Àü¹°Áú µµÀÔ È¿À²ÀÌ ³ô¾Æ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

½Å°æÁúȯ ºÐ¾ß´Â ÆÄŲ½¼º´, ô¼ö¼º ±ÙÀ§ÃàÁõ(SMA), ÇåÆÃÅϺ´°ú °°Àº ÁúȯÀÇ Ä¡·á¸¦ ȹ±âÀûÀ¸·Î º¯È­½Ãų ¼ö ÀÖ´Â Å« ÀáÀç·ÂÀ» Áö´Ñ À¯ÀüÀÚ Ä¡·áÀÇ ÁÖ¿ä ÀÀ¿ë ºÐ¾ß·Î Å« ¼ºÀåÀÌ ±â´ëµÇ´Â ºÐ¾ßÀÔ´Ï´Ù.

2024³â¿¡´Â ºÏ¹Ì°¡ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ªÀº ¼±ÁøÀûÀÎ ÀÇ·á ÀÎÇÁ¶ó, °­·ÂÇÑ Á¤ºÎ Áö¿ø, Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ ³ôÀº R&D ºñ¿ëÀÇ ÇýÅÃÀ» ´©¸®°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀåÀº ÇコÄɾî ÅõÀÚ Áõ°¡, »ý¸í°øÇÐ ºÐ¾ß È®´ë, ±ÔÁ¦ ü°è °³¼±À¸·Î ÀÎÇØ Å« ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ±â¾÷À¸·Î´Â Andelyn Biosciences, AstraZeneca, Autolomous Ltd, BioIT, DEEP GENOMICS, ElevateBio, IBM, IDBS, L7 Informatics, Lonza, Novartis, Precision BioSciences, Renova Therapeutics, SAP SE, Sarepta Therapeutics, TrakCare, Novartis, SAP SE, Sarepta Therapeutics, TrakCare, Novartis, Precision BioSciences, Sarepta Therapeutics, SAP SE, SAP, Traxa Therapeutics, TrakCare, Traxa Therapeutics, TrakCare Novartis, Precision BioSciences, Renova Therapeutics, SAP SE, Sarepta Therapeutics, TrakCel µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ÇöȲ
  • À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PESTEL ºÐ¼®
  • À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå : Ç÷§Æûº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ¹ÙÀÌ·¯½º º¤ÅÍ Ç÷§Æû
  • ºñ¹ÙÀÌ·¯½º º¤ÅÍ Ç÷§Æû
  • À¯ÀüÀÚ ÆíÁý Ç÷§Æû
  • CRISPR-Cas ½Ã½ºÅÛ
  • TALENs
  • ZFN

Á¦6Àå ¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå : ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Á¾¾çÇÐ
  • Èñ¼Ò À¯Àü¼º Áúȯ
  • ½ÉÇ÷°üÁúȯ
  • ½Å°æÁúȯ
  • ¾È°úÁúȯ
  • Ç÷¾×Áúȯ
  • ±Ù°ñ°Ý°è Àå¾Ö
  • °¨¿°Áõ

Á¦7Àå ¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå : Àü´Þ ¸ðµåº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • »ýü³»
  • »ýü¿Ü
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¿¬±¸±â°ü
  • °è¾à °³¹ß Á¦Á¶ Á¶Á÷(CDMO)
  • º´¿ø ¹× À¯ÀüÀÚ Ä¡·á ¼¾ÅÍ

Á¦9Àå ¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • À¯ÀüÀÚ Ä¡·á Ç÷§Æû ½ÃÀå Æò°¡ : Áö¿ª, 2020³â-2034³â
  • ºÏ¹Ì
    • ºÏ¹Ì : Ç÷§Æûº°, 2020³â-2034³â
    • ºÏ¹Ì : ¿ëµµº°, 2020³â-2034³â
    • ºÏ¹Ì : Àü´Þ ¸ðµåº°, 2020³â-2034³â
    • ºÏ¹Ì : ÃÖÁ¾ ¿ëµµº°, 2020³â-2034³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ : Ç÷§Æûº°, 2020³â-2034³â
    • À¯·´ : ¿ëµµº°, 2020³â-2034³â
    • À¯·´ : Àü´Þ ¸ðµåº°, 2020³â-2034³â
    • À¯·´ : ÃÖÁ¾ ¿ëµµº°, 2020³â-2034³â
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Ç÷§Æûº°, 2020³â-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¿ëµµº°, 2020³â-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Àü´Þ ¸ðµåº°, 2020³â-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾ ¿ëµµº°, 2020³â-2034³â
    • Áß±¹
    • Àεµ
    • ¸»·¹À̽þÆ
    • ÀϺ»
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Ç÷§Æûº°, 2020³â-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¿ëµµº°, 2020³â-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Àü´Þ ¸ðµåº°, 2020³â-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020³â-2034³â
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : Ç÷§Æûº°, 2020³â-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¿ëµµº°, 2020³â-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : Àü´Þ ¸ðµåº°, 2020³â-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020³â-2034³â
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • È®´ë¿Í Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦11Àå ±â¾÷ °³¿ä

  • Andelyn Biosciences
  • AstraZeneca
  • Autolomous Ltd
  • BioIT
  • DEEP GENOMICS
  • ElevateBio
  • IBM
  • IDBS
  • L7 Informatics, Inc.
  • Lonza
  • Novartis
  • Precision BioSciences
  • Renova Therapeutics
  • SAP SE
  • Sarepta Therapeutics, Inc.
  • TrakCel
LSH 25.07.10

The gene therapy platform market size is expected to reach USD 11,035.41 million by 2034, according to a new study by Polaris Market Research. The report "Gene Therapy Platform Market Size, Share, & Trends Analysis Report: By Platform Type, By Application, By Delivery Mode (In Vivo, Ex Vivo, and Other), By End Use, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

A gene therapy platform is a comprehensive system or technology used to develop, deliver, and manufacture gene-based treatments that modify or replace faulty genes to treat or prevent diseases. Investments in gene therapy have surged, with millions of dollars flowing from governments, venture capitalists, and pharmaceutical companies into research and development. This financial support enables biotech startups and research institutions to innovate faster, conduct clinical trials, and bring new therapies to market. The high potential of gene therapy to cure rare and serious diseases makes it an attractive area for investors. Mergers and acquisitions, and collaborations among companies are increasing, helping to build stronger platforms and pipelines. This strong financial backing is essential for advancing gene therapy technologies and expanding their reach to more patients globally.

The increasing number of successful clinical trials and regulatory approvals for gene therapy products boosts confidence in this treatment approach. Therapies such as Zolgensma for spinal muscular atrophy and Luxturna for inherited vision loss have shown promising, often life-changing results. Positive trial outcomes demonstrate real-world safety and effectiveness, encouraging research and investment. As more therapies receive approval, it validates the potential of gene therapy and drives broader acceptance by doctors, patients, and payers. These successes are paving the way for a new generation of treatments, creating momentum and expanding the scope of the gene therapy platform market.

Gene Therapy Platform Market Report Highlights

In 2024, the viral vector platforms segment dominated with the largest share due to their high efficiency in delivering genetic material into cells.

The neurological disorders segment is expected to experience significant growth as it is a major application area for gene therapy, with significant potential to transform treatment for diseases such as Parkinson's, spinal muscular atrophy (SMA), and Huntington's disease.

In 2024, the North America gene therapy platform market dominated with the largest share as the region benefits from advanced healthcare infrastructure, strong government support, and high R&D spending by pharmaceutical and biotech companies.

The Asia Pacific gene therapy platform market is experiencing significant growth due to rising healthcare investments, expanding biotech sectors, and improving regulatory frameworks.

A few global key market players are Andelyn Biosciences; AstraZeneca; Autolomous Ltd; BioIT; DEEP GENOMICS; ElevateBio; IBM; IDBS; L7 Informatics, Inc.; Lonza; Novartis; Precision BioSciences; Renova Therapeutics; SAP SE; Sarepta Therapeutics, Inc.; and TrakCel.

Polaris Market Research has segmented the gene therapy platform market report on the basis of platform type, application, delivery mode, end use, and region:

By Platform Type (Revenue - USD Million, 2020-2034)

Viral Vector Platforms

Adeno-Associated Virus (AAV)

Lentivirus

Retrovirus

Adenovirus

Herpes Simplex Virus (HSV)

Non-Viral Vector Platforms

Lipid Nanoparticles (LNPs)

Electroporation & Microinjection Platforms

Polymer-Based Delivery Systems

Naked DNA/RNA Delivery

Gene Editing Platforms

CRISPR-Cas Systems

TALENs

ZFNs

By Application (Revenue - USD Million, 2020-2034)

Oncology

Rare Genetic Disorders

Cardiovascular Diseases

Neurological Disorders

Ophthalmic Diseases

Hematological Disorders

Musculoskeletal Disorders

Infectious Diseases

By Delivery Mode (Revenue - USD Million, 2020-2034)

In Vivo

Ex Vivo

Other

By End Use (Revenue - USD Million, 2020-2034)

Pharmaceutical & Biotechnology Companies

Academic & Research Institutions

Contract Development & Manufacturing Organizations (CDMOs)

Hospitals & Gene Therapy Centers

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America

US

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Gene Therapy Platform Market Insights

  • 4.1. Gene Therapy Platform Market - Market Snapshot
  • 4.2. Gene Therapy Platform Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Demand for Personalized Medicine
      • 4.2.1.2. Growing Prevalence of Genetic Disorder
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Initial Investment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Gene Therapy Platform Market Trends
  • 4.6. Value Chain Analysis

5. Global Gene Therapy Platform Market, by Platform

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
  • 5.3. Viral Vector Platforms
    • 5.3.1. Global Gene Therapy Platform Market, by Viral Vector Platforms, by Region, 2020-2034 (USD Million)
    • 5.3.2. Adeno-associated Virus (AAV)
      • 5.3.2.1. Global Gene Therapy Platform Market, by Adeno-associated Virus (AAV), by Region, 2020-2034 (USD Million)
    • 5.3.3. Lentivirus
      • 5.3.3.1. Global Gene Therapy Platform Market, by Lentivirus, by Region, 2020-2034 (USD Million)
    • 5.3.4. Retrovirus
      • 5.3.4.1. Global Gene Therapy Platform Market, by Retrovirus, by Region, 2020-2034 (USD Million)
    • 5.3.5. Adenovirus
      • 5.3.5.1. Global Gene Therapy Platform Market, by Adenovirus, by Region, 2020-2034 (USD Million)
    • 5.3.6. Herpes Simplex Virus (HSV)
      • 5.3.6.1. Global Gene Therapy Platform Market, by Herpes Simplex Virus (HSV), by Region, 2020-2034 (USD Million)
  • 5.4. Non-Viral Vector Platforms
    • 5.4.1. Global Gene Therapy Platform Market, by Non-Viral Vector Platforms, by Region, 2020-2034 (USD Million)
    • 5.4.2. Lipid Nanoparticles (LNPs)
      • 5.4.2.1. Global Gene Therapy Platform Market, by Lipid Nanoparticles (LNPs), by Region, 2020-2034 (USD Million)
    • 5.4.3. Electroporation & Microinjection Platforms
      • 5.4.3.1. Global Gene Therapy Platform Market, by Electroporation & Microinjection Platforms by Region, 2020-2034 (USD Million)
    • 5.4.4. Polymer-based Delivery Systems
      • 5.4.4.1. Global Gene Therapy Platform Market, by Polymer-based Delivery Systems by Region, 2020-2034 (USD Million)
    • 5.4.5. Naked DNA/RNA Delivery
      • 5.4.5.1. Global Gene Therapy Platform Market, by Naked DNA/RNA Delivery by Region, 2020-2034 (USD Million)
  • 5.5. Gene Editing Platforms
    • 5.5.1. Global Gene Therapy Platform Market, by Gene Editing Platforms by Region, 2020-2034 (USD Million)
  • 5.6. CRISPR-Cas Systems
    • 5.6.1. Global Gene Therapy Platform Market, by CRISPR-Cas Systems by Region, 2020-2034 (USD Million)
  • 5.7. TALENs
    • 5.7.1. Global Gene Therapy Platform Market, by TALENs by Region, 2020-2034 (USD Million)
  • 5.8. ZFNs
    • 5.8.1. Global Gene Therapy Platform Market, by ZFNs by Region, 2020-2034 (USD Million)
    • 5.8.2.

6. Global Gene Therapy Platform Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
  • 6.3. Oncology
    • 6.3.1. Global Gene Therapy Platform Market, by Oncology, by Region, 2020-2034 (USD Million)
  • 6.4. Rare Genetic Disorders
    • 6.4.1. Global Gene Therapy Platform Market, by Rare Genetic Disorders, by Region, 2020-2034 (USD Million)
  • 6.5. Cardiovascular Diseases
    • 6.5.1. Global Gene Therapy Platform Market, by Cardiovascular Diseases, by Region, 2020-2034 (USD Million)
  • 6.6. Neurological Disorders
    • 6.6.1. Global Gene Therapy Platform Market, by Neurological Disorders, by Region, 2020-2034 (USD Million)
  • 6.7. Ophthalmic Diseases
    • 6.7.1. Global Gene Therapy Platform Market, by Ophthalmic Diseases, by Region, 2020-2034 (USD Million)
  • 6.8. Hematological Disorders
    • 6.8.1. Global Gene Therapy Platform Market, by Hematological Disorders, by Region, 2020-2034 (USD Million)
  • 6.9. Musculoskeletal Disorders
    • 6.9.1. Global Gene Therapy Platform Market, by Musculoskeletal Disorders, by Region, 2020-2034 (USD Million)
  • 6.10. Infectious Diseases
    • 6.10.1. Global Gene Therapy Platform Market, by Infectious Diseases, by Region, 2020-2034 (USD Million)

7. Global Gene Therapy Platform Market, by Delivery Mode

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Gene Therapy Platform Market, by Medical Biotechnology, 2020-2034 (USD Million)
  • 7.3. In Vivo
    • 7.3.1. Global Gene Therapy Platform Market, by In Vivo, by Region, 2020-2034 (USD Million)
  • 7.4. Ex Vivo
    • 7.4.1. Global Gene Therapy Platform Market, by Ex Vivo, by Region, 2020-2034 (USD Million)
  • 7.5. Other
    • 7.5.1. Global Gene Therapy Platform Market, by Other, by Region, 2020-2034 (USD Million)

8. Global Gene Therapy Platform Market, by End Use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
  • 8.3. Pharmaceutical & Biotechnology Companies
    • 8.3.1. Global Gene Therapy Platform Market, by Pharmaceutical & Biotechnology Companies, by Region, 2020-2034 (USD Million)
  • 8.4. Academic & Research Institutions
    • 8.4.1. Global Gene Therapy Platform Market, by Academic & Research Institutions, by Region, 2020-2034 (USD Million)
  • 8.5. Contract Development & Manufacturing Organizations (CDMOs)
    • 8.5.1. Global Gene Therapy Platform Market, by Contract Development & Manufacturing Organizations (CDMOs), 2020-2034 (USD Million)
  • 8.6. Hospitals & Gene Therapy Centers
    • 8.6.1. Global Gene Therapy Platform Market, by Hospitals & Gene Therapy Centers, by Region, 2020-2034 (USD Million)

9. Global Gene Therapy Platform Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Gene Therapy Platform Market Assessment, By Geography, 2020-2034 (USD Million)
  • 9.3. Gene Therapy Platform Market - North America
    • 9.3.1. North America: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
    • 9.3.2. North America: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
    • 9.3.3. North America: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
    • 9.3.4. North America: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.3.5. Gene Therapy Platform Market - US
      • 9.3.5.1. US: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.3.5.2. US: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.3.5.3. US: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.3.5.4. US: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.3.6. Gene Therapy Platform Market - Canada
      • 9.3.6.1. Canada: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.3.6.2. Canada: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.3.6.3. Canada: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.3.6.4. Canada: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
  • 9.4. Gene Therapy Platform Market - Europe
    • 9.4.1. Europe: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
    • 9.4.2. Europe: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
    • 9.4.3. Europe: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
    • 9.4.4. Europe: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.5. Gene Therapy Platform Market - UK
      • 9.4.5.1. UK: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.5.2. UK: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.5.3. UK: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.5.4. UK: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.6. Gene Therapy Platform Market - France
      • 9.4.6.1. France: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.6.2. France: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.6.3. France: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.6.4. France: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.7. Gene Therapy Platform Market - Germany
      • 9.4.7.1. Germany: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.7.2. Germany: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.7.3. Germany: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.7.4. Germany: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.8. Gene Therapy Platform Market - Italy
      • 9.4.8.1. Italy: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.8.2. Italy: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.8.3. Italy: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.8.4. Italy: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.9. Gene Therapy Platform Market - Spain
      • 9.4.9.1. Spain: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.9.2. Spain: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.9.3. Spain: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.9.4. Spain: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.10. Gene Therapy Platform Market - Netherlands
      • 9.4.10.1. Netherlands: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.10.2. Netherlands: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.10.3. Netherlands: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.10.4. Netherlands: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.11. Gene Therapy Platform Market - Russia
      • 9.4.11.1. Russia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.11.2. Russia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.11.3. Russia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.11.4. Russia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.4.12. Gene Therapy Platform Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.4.12.2. Rest of Europe: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.4.12.3. Rest of Europe: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.4.12.4. Rest of Europe: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
  • 9.5. Gene Therapy Platform Market - Asia Pacific
    • 9.5.1. Asia Pacific: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
    • 9.5.2. Asia Pacific: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
    • 9.5.3. Asia Pacific: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
    • 9.5.4. Asia Pacific: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.5. Gene Therapy Platform Market - China
      • 9.5.5.1. China: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.5.2. China: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.5.3. China: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.5.4. China: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.6. Gene Therapy Platform Market - India
      • 9.5.6.1. India: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.6.2. India: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.6.3. India: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.6.4. India: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.7. Gene Therapy Platform Market - Malaysia
      • 9.5.7.1. Malaysia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.7.2. Malaysia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.7.3. Malaysia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.7.4. Malaysia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.8. Gene Therapy Platform Market - Japan
      • 9.5.8.1. Japan: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.8.2. Japan: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.8.3. Japan: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.8.4. Japan: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.9. Gene Therapy Platform Market - Indonesia
      • 9.5.9.1. Indonesia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.9.2. Indonesia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.9.3. Indonesia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.9.4. Indonesia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.10. Gene Therapy Platform Market - South Korea
      • 9.5.10.1. South Korea: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.10.2. South Korea: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.10.3. South Korea: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.10.4. South Korea: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.11. Gene Therapy Platform Market - Australia
      • 9.5.11.1. Australia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.11.2. Australia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.11.3. Australia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.11.4. Australia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.5.12. Gene Therapy Platform Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.5.12.2. Rest of Asia Pacific: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.5.12.3. Rest of Asia Pacific: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.5.12.4. Rest of Asia Pacific: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
  • 9.6. Gene Therapy Platform Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
    • 9.6.2. Middle East & Africa: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
    • 9.6.3. Middle East & Africa: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
    • 9.6.4. Middle East & Africa: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.6.5. Gene Therapy Platform Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.6.5.2. Saudi Arabia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.6.5.3. Saudi Arabia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.6.5.4. Saudi Arabia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.6.6. Gene Therapy Platform Market - UAE
      • 9.6.6.1. UAE: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.6.6.2. UAE: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.6.6.3. UAE: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.6.6.4. UAE: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.6.7. Gene Therapy Platform Market - Israel
      • 9.6.7.1. Israel: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.6.7.2. Israel: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.6.7.3. Israel: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.6.7.4. Israel: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.6.8. Gene Therapy Platform Market - South Africa
      • 9.6.8.1. South Africa: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.6.8.2. South Africa: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.6.8.3. South Africa: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.6.8.4. South Africa: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.6.9. Gene Therapy Platform Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.6.9.2. Rest of Middle East & Africa: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.6.9.3. Rest of Middle East & Africa: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.6.9.4. Rest of Middle East & Africa: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
  • 9.7. Gene Therapy Platform Market - Latin America
    • 9.7.1. Latin America: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
    • 9.7.2. Latin America: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
    • 9.7.3. Latin America: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
    • 9.7.4. Latin America: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.7.5. Gene Therapy Platform Market - Mexico
      • 9.7.5.1. Mexico: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.7.5.2. Mexico: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.7.5.3. Mexico: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.7.5.4. Mexico: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.7.6. Gene Therapy Platform Market - Brazil
      • 9.7.6.1. Brazil: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.7.6.2. Brazil: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.7.6.3. Brazil: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.7.6.4. Brazil: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.7.7. Gene Therapy Platform Market - Argentina
      • 9.7.7.1. Argentina: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.7.7.2. Argentina: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.7.7.3. Argentina: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.7.7.4. Argentina: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
    • 9.7.8. Gene Therapy Platform Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
      • 9.7.8.2. Rest of Latin America: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
      • 9.7.8.3. Rest of Latin America: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
      • 9.7.8.4. Rest of Latin America: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Andelyn Biosciences
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. AstraZeneca
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Autolomous Ltd
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. BioIT
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. DEEP GENOMICS
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. ElevateBio
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. IBM
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. IDBS
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. L7 Informatics, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Lonza
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Novartis
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Precision BioSciences
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Renova Therapeutics
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. SAP SE
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Sarepta Therapeutics, Inc.
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. TrakCel
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦